Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 3:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: 5 mg saxagliptin Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo matching with Saxagliptin, Metformin IR, Metformin XR, Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 10 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 7
States / cities: Los Angeles, California • Tallahassee, Florida • Dearborn, Michigan + 4 more

Conditions: Diabetes Mellitus, Type 2, Impaired Glucose Tolerance (IGT), Impaired Fasting Glucose (IFG)
Interventions: Dapagliflozin, Saxagliptin, Pioglitazone, Metformin; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 65 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2027
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes Mellitus
Interventions: Saxagliptin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 18,206 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 202
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 199 more

Conditions: Polycystic Ovary Syndrome, Disorder of Glucose Regulation
Interventions: Metformin XR, Saxagliptin, Saxagliptin-Metformin XR; Drug
Lead sponsor: Woman's; Other
Eligibility: 18 Years to 42 Years · Female only
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Type 2 Diabetes
Interventions: Dapagliflozin, Placebo matching with Dapagliflozin, Saxagliptin, Metformin immediate release (IR); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 26
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 21 more

Conditions: Bioequivalence, Log-transformed AUCss and Cmax,ss Values for Saxagliptin and Metformin
Interventions: Onglyza (saxagliptin), Diabex, 5-mg saxagliptin/1000 mg metformin, 5-mg saxagliptin/500 mg metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Type 2 Diabetes Mellitus, Heart Failure
Interventions: Saxagliptin, Sitagliptin, Placebo to match saxagliptin, Placebo to match sitagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 11
States / cities: Torrance, California • Upland, California • Miami, Florida + 7 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Dapagliflozin, Sitagliptin, Placebo matching with Saxagliptin, Placebo matching with Dapagliflozin, Placebo matching with Sitagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 461 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 40
States / cities: Mesa, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 34 more

Conditions: Diabetes
Interventions: Saxagliptin, Metformin, Placebo, pioglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 1,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Concord, California • Encinitas, California • Orange, California + 38 more

Conditions: Diabetes Mellitus
Interventions: saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus
Interventions: saxagliptin, Glucophage XR, saxagliptin + metformin XR (FDC tablet); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Diabetes Mellitus Type 2, Hyperglycemia
Interventions: Glipizide XL, Saxagliptin + Metformin XR, Metformin XR; Drug
Lead sponsor: Cook County Health; Government
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Type 2 Diabetes, Hypertriglyceridemia
Interventions: Saxagliptin; Drug
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2024
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases
Interventions: Dapagliflozin 10mg, Saxagliptin 5mg, Placebo Oral Tablet; Drug
Lead sponsor: Sabyasachi Sen; Other
Eligibility: 30 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Prediabetes, Obesity
Interventions: Exenatide, Saxagliptin, Exenatide extended-release (ER), Placebo; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 30 Years to 70 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Diabetes
Interventions: Saxagliptin, Placebo, metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 77 Years
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 51
States / cities: Columbiana, Alabama • Haleyville, Alabama • Mesa, Arizona + 45 more

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Placebo, Metformin (blinded), Metformin (open-label); Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 156 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 3
States / cities: San Diego, California • Baton Rouge, Louisiana • San Antonio, Texas

Conditions: Diabetes
Interventions: Saxagliptin/Metformin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes Mellitus, Type 2
Interventions: Saxagliptin, Dapagliflozin, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 18 Years to 70 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Search by objective public record fields.

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

Pre-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glucose Tolerance (IGT)

Does Saxagliptin Reduce the Risk of Cardiovascular Events When Used Alone or Added to Other Diabetes Medications

Saxagliptin + Metformin Compared to Saxagliptin or Metformin Monotherapy in PCOS Women With Impaired Glucose Homeostasis

Safety and Efficacy of Dapagliflozin in Triple Therapy to Treat Subjects With Type 2 Diabetes

Study in Healthy Subjects to Measure Amount of Drug in Blood After Dosing With Different Saxagliptin / Metformin Produc

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

Study to Evaluate the Efficacy and Safety of Saxagliptin Co-administered With Dapagliflozin in Combination With Metformin Compared to Sitagliptin in Combination With Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Therapy Alone

A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin/1000 mg Metformin XR (Manufactured in Mt Vernon, IN) Relative to 5 mg of Onglyza and 2 × 500 mg Glucophage XR

Outpatient Discharge Therapy With Saxagliptin+MetforminXR vs GlipizideXL for Type 2 Diabetes With Severe Hyperglycemia

Effects of DPP-4 Inhibition on Triglycerides

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Effects of Antidiabetic Medications on the Postprandial State in Prediabetes

Study of BMS-477118 as Monotherapy With Titration in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

A Study Assessing Saxagliptin Treatment in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise

Bioequivalence Study

ESR-15-11293 - Saxa/Dapa, Safety and Efficacy Study